Evaluation of antibody and T Cell immunity response in different immunization groups of inactive and mRNA COVID-19 vaccines.

ABSTRACT

This study aimed to evaluate the antibody and T cell responses of homologous and heterologous booster doses for SARS-CoV-2 vaccines. Our study was performed on those with two doses of mRNA vaccine BNT162b2 (2B, n44), those with heterologous booster dose BNT162b2 vaccine after two doses of inactivated vaccine CoronaVac (2S+1B, n44), those with homologous booster dose vaccine CoronaVac after two doses of vaccine CoronaVac (3S, n44) SARS-CoV-2 IgG antibody levels were significantly higher in individuals who received heterologous boosters(p<0.001). IFN-Ɣ, IL-2 and IL-13 median values were detected higher in 2S+1B group than in 3S group, respectively (p=0.112, p=0.057, p=0.341). Although the antibody levels in 2S+1B group were similar (p=0.153) to the 2B group; IFN-Ɣ, IL-2 and IL-13 levels were higher (p<0.001). In conclusion, supplementing an improved strategy based on inactivated vaccines with an mRNA vaccine as a heterologous booster is likely to be more beneficial in the course of the pandemic.